- Home
- SMXT vs PRLD Comparison
SMXT vs PRLD Comparison
Compare SMXT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMXT
- PRLD
- Stock Information
- Founded
- SMXT 2008
- PRLD 2016
- Country
- SMXT United States
- PRLD United States
- Employees
- SMXT N/A
- PRLD N/A
- Industry
- SMXT
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- SMXT
- PRLD Health Care
- Exchange
- SMXT NYSE
- PRLD Nasdaq
- Market Cap
- SMXT 58.9M
- PRLD 50.1M
- IPO Year
- SMXT 2024
- PRLD 2020
- Fundamental
- Price
- SMXT $1.13
- PRLD $0.78
- Analyst Decision
- SMXT
- PRLD Strong Buy
- Analyst Count
- SMXT 0
- PRLD 2
- Target Price
- SMXT N/A
- PRLD $4.50
- AVG Volume (30 Days)
- SMXT 96.5K
- PRLD 107.5K
- Earning Date
- SMXT 05-19-2025
- PRLD 05-06-2025
- Dividend Yield
- SMXT N/A
- PRLD N/A
- EPS Growth
- SMXT N/A
- PRLD N/A
- EPS
- SMXT N/A
- PRLD N/A
- Revenue
- SMXT $22,986,881.00
- PRLD $7,000,000.00
- Revenue This Year
- SMXT N/A
- PRLD N/A
- Revenue Next Year
- SMXT N/A
- PRLD N/A
- P/E Ratio
- SMXT N/A
- PRLD N/A
- Revenue Growth
- SMXT N/A
- PRLD N/A
- 52 Week Low
- SMXT $0.60
- PRLD $0.61
- 52 Week High
- SMXT $13.48
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- SMXT N/A
- PRLD 46.96
- Support Level
- SMXT N/A
- PRLD $0.73
- Resistance Level
- SMXT N/A
- PRLD $1.00
- Average True Range (ATR)
- SMXT 0.00
- PRLD 0.09
- MACD
- SMXT 0.00
- PRLD -0.01
- Stochastic Oscillator
- SMXT 0.00
- PRLD 18.96
About SMXT SOLARMAX TECHNOLOGY INC
SolarMax Technology Inc is an integrated solar and renewable energy company. It operates in two segments namely the United States and China. The United States business includes the sale and installation of photovoltaic and battery backup systems. China operations consist of operating and maintaining solar farm projects and identifying and procuring solar farm projects for resale to third parties. Some of its products are LG Solar Panels, QCELL Solar Panels, Panasonic Solar Panels, and others. The company generates a majority of its revenue from the Solar energy systems.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.